论文部分内容阅读
目的探讨雌激素对绝经后骨质疏松症 (postmenopausalosteoporosis,PMO)的防治作用。 方法本研究用QCT法测定腰椎L2 ～L4 骨密度 ,并行骨代谢一般生化指标测试 ,观察 48例绝经后妇女的骨量变化 ,用天然结合雌激素倍美力防治骨质疏松的作用。 结果 48例研究对象治疗前均有骨密度下降 ,其中 32人患有骨质疏松 ,占 6 6 .6 7% ;未用倍美力治疗者 2 3例 (对照组 )骨密度继续下降 ,自身对照有显著差异 (P <0 .0 1) ;倍美力 0 .6 2 5mg/d治疗者 2 5例 (治疗组 ) ,一年后测试骨密度无明显变化 ,说明倍美力能减缓骨密度下降。治疗组服用倍美力后尿钙 /肌酐、尿羟脯氨酸 /肌肝比值均有下降 (P <0 .0 5 ) ,对照组则不明显 ,两组治疗后尿羟脯氨酸 /肌肝比值有明显差异 (P <0 .0 5 )。 结论提示倍美力能有效地减缓骨吸收速度 ,减少骨质丢失 ,从而防止骨质疏松的发生。
Objective To investigate the preventive and therapeutic effects of estrogen on postmenopausal osteoporosis (PMO). Methods In this study, bone mineral density (L2 ~ L4) of lumbar spine was measured by QCT method and the general biochemical indexes of bone metabolism were tested. The bone mass changes were observed in 48 cases of postmenopausal women and the effect of combining natural estrogen and betamethasone on prevention and treatment of osteoporosis. Results All the 48 subjects had decreased BMD before treatment, 32 of them had osteoporosis, accounting for 66.67%. The BMD of 23 patients who did not receive beibei force continued to decline There was significant difference between the two groups (P <0.01). There was no significant change in BMD after one year (P <0.01) Decreased density. Urinary calcium / creatinine, urinary hydroxyproline / muscle ratio decreased (P <0. 05) in the treatment group after taking betamethasone, but not in the control group. After treatment, urinary hydroxyproline / Liver ratio was significantly different (P <0. 05). Conclusions suggest that the times of the United States can effectively reduce the rate of bone resorption and reduce bone loss, thereby preventing the occurrence of osteoporosis.